PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies

Tuesday, December 9, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, Dec. 9 PAREXEL International Corporation(Nasdaq: PRXL), a leading global biopharmaceutical services provider,announced today that it has established an alliance with Safe Implementationof Treatments in Stroke (SITS) International, the world's largest network ofclinical sites with specialized capabilities in the area of stroke. Throughthis alliance, PAREXEL's clients benefit from SITS' access to more than 800investigator sites located in 40 countries, which are dedicated to thetreatment of patients suffering from acute stroke and to the conduct of PhaseII - IV stroke-related clinical studies.

"According to the World Health Organization, 15 million people suffer fromstroke worldwide each year, and with the aging population, biopharmaceuticalcompanies are turning to PAREXEL with respect to an increasing number ofclinical programs focused on advancing new stroke treatments," according toMark A. Goldberg, M.D., Chief Operating Officer, PAREXEL. "PAREXEL's alliancewith SITS is representative of our dedication to providing clients withexpanded capabilities in the area of stroke, including accelerated studystart-up and patient recruitment for clinical development programs. We arepleased to combine our in-depth central nervous system therapeutic areaexpertise with the highly specialized capabilities of SITS to help clientsexecute stroke-related studies more efficiently on a global basis."

"In joining forces with PAREXEL, SITS looks forward to furthering thegrowing field of stroke research and speeding the introduction of importanttreatments to patients," said Nils Wahlgren, M.D., Ph.D., Chairman of SITSInternational. "We look forward to working with PAREXEL to implement strokeprograms throughout our expanding network of sites."

The objective of SITS International is the broad implementation ofevidence-based stroke care and the amplification of its effects bybenchmarking against best practices to certify excellence in stroke treatment.SITS is an academic-driven international collaborative, which serves as aplatform for stroke-related clinical research. Through the SITS alliance,PAREXEL offers its clients a broad range of stroke-related program options,including clinical, post marketing, and safety studies, as well as patientregistries. PAREXEL leverages SITS-developed tools in feasibility studymodeling and site selection for its clients' clinical studies.

For more information about PAREXEL's Clinical Research Services, visit:

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceuticalservices organization, providing a broad range of knowledge-based contractresearch, medical communications and consulting services to the worldwidepharmaceutical, biotechnology and medical device industries. Committed toproviding solutions that expedite time-to-market and peak-market penetration,PAREXEL has developed significant expertise across the development andcommercialization continuum, from drug development and regulatory consultingto clinical pharmacology, clinical trials management, medical education andreimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, providesadvanced technology solutions, including medical imaging, to facilitate theclinical development process. Headquartered near Boston, Massachusetts,PAREXEL operates in 71 locations throughout 52 countries around the world, andhas over 9,180 employees. For more information about PAREXEL Internationalvisit

This release contains "forward-looking" statements regarding futureresults and events. For this purpose, any statements contained herein that arenot statements of historical fact may be deemed forward-looking statements.Without limiting the foregoing, the words "believes," "anticipates," "plans,""expects," "intends," "appears," "estimates," "projects," "targets," andsimilar expressions are also intended to identify forward-looking statements.The forward-looking statements in this release involve a number of risks anduncertainties. The Company's actual future results may differ significantlyfrom the results discussed in the forward-looking statements contained in thisrelease. Important factors that might cause such a difference include, but arenot limited to, risks associated with: actual operating performance; actualexpense savings and other operating improvements resulting from recentrestructurings; the loss, modification, or delay of contracts which would,among other things, adversely impact the Company's recognition of revenueincluded in backlog; the Company's dependence on certain industries andclients; the Company's ability to win new business, manage growth and costs,and attract and retain employees; the Company's ability to complete additionalacquisitions and to integrate newly acquired businesses or enter into newlines of business, including, but not limited to, the successful businessintegration and anticipated synergy achievements in connection with theClinPhone acquisition; the impact on the Company's business of governmentregulation of the drug, medical device and biotechnology industry;consolidation within the pharmaceutical industry and competition within thebiopharmaceutical services industry; the potential for significant liabilityto clients and third parties; the potential adverse impact of health carereform; and the effects of exchange rate fluctuations and other internationaleconomic, political, and other risks. Such factors and others are discussedmore fully in the section entitled "Risk Factors" of the Company's QuarterlyReport on Form 10-Q for the quarter ended September 30, 2008 as filed with theSEC on November 7, 2008, which "Risk Factors" discussion is incorporated byreference in this press release. The forward-looking statements included inthis press release represent the Company's estimates as of the date of thisrelease. The Company specifically disclaims any obligation to update theseforward-looking statements in the future. These forward-looking statementsshould not be relied upon as representing the Company's estimates or views asof any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation,and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. Allother names or marks may be registered trademarks or trademarks of PAREXELInternational Corporation, Perceptive Informatics, Inc. or their respectiveowners and are hereby acknowledged.Contacts: Jennifer Baird, Senior Director of Public Relations PAREXEL International Tel: +781-434-4409 Email: Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email:

SOURCE PAREXEL International Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store